Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Outperform on Acuity Brands, Lowers Price Target to $200

Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.
byBenzinga Newsdesk
July 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Reported Late Thursday March 2, Dispute Between Treace Medical and Fusion Orthopedics Resolved; Parties Entered Into An Agreement To Settle This Matter. While The Terms Of The Settlement Are Confidential, Fusion Orthopedics Is Pleased With The Outcome

By Happy Mohamed
March 3, 1:34 AM
Treace Medical Concepts, Inc. (NASDAQ:TMCI) ("Treace Medical") and Fusion Orthopedics, LLC ("Fusion Orthopedics") jointly announce that they have reached an amicable resolution of the litigation

TMCI